Cynapsus Therapeutics Inc.

Cynapsus Therapeutics Inc. is a specialty pharmaceutical company developing a fast-acting, easy-to-use, sublingual, thin film for the on-demand management of debilitating "off" episodes associated with Parkinson's Disease. The current method of delivery is an inconvenient and painful injection. The reformulation could address a large moderate-to-severe patient population, approximately 25–50% of all Parkinson's patients. The potential annual market could grow to well beyond $1B/year. The company plans to derisk the project over the next two years, after which a new drug application can be submitted.